1. Home
  2. SABR vs LYEL Comparison

SABR vs LYEL Comparison

Compare SABR & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sabre Corporation

SABR

Sabre Corporation

HOLD

Current Price

$1.55

Market Cap

489.7M

Sector

Technology

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$22.00

Market Cap

490.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SABR
LYEL
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
489.7M
490.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
SABR
LYEL
Price
$1.55
$22.00
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$3.70
$25.00
AVG Volume (30 Days)
16.7M
94.8K
Earning Date
05-21-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
283.56
N/A
EPS
1.34
N/A
Revenue
$3,866,956,000.00
$61,000.00
Revenue This Year
$7.40
N/A
Revenue Next Year
$3.26
N/A
P/E Ratio
$1.20
N/A
Revenue Growth
7.46
N/A
52 Week Low
$0.81
$0.39
52 Week High
$3.86
$45.00

Technical Indicators

Market Signals
Indicator
SABR
LYEL
Relative Strength Index (RSI) 58.34 42.39
Support Level $1.20 $21.27
Resistance Level $1.70 $27.30
Average True Range (ATR) 0.22 2.05
MACD 0.09 -0.01
Stochastic Oscillator 64.29 29.36

Price Performance

Historical Comparison
SABR
LYEL

About SABR Sabre Corporation

Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company sold its growing hotel IT solutions division (9% of revenue) to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Share on Social Networks: